It is the cache of http://ebioscholar.com/ojs/index.php/ijb/article/view/35. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

COMPARISION OF EFFICACY OF STAVUDINE AND ZIDOVUDINE ON CD4 COUNTS IN TRIPLE DRUG THERAPY REGIMEN IN PATIENTS WITH HIV INFECTION - A RETROSPECTIVE STUDY | Gokul CG, Santhosh Ramakrishna, Narendranath S | International Journal of Bioassays

COMPARISION OF EFFICACY OF STAVUDINE AND ZIDOVUDINE ON CD4 COUNTS IN TRIPLE DRUG THERAPY REGIMEN IN PATIENTS WITH HIV INFECTION - A RETROSPECTIVE STUDY

Kiran LJ*, Gokul CG, Santhosh Ramakrishna, Narendranath S

Abstract


The main objective of the study is 1. To compare the effect of triple drug therapy with stavudine + lamivudine + nevirapine on CD4 counts 6months and 12 months after therapy. 2. To compare the effect of triple drug therapy with zidovudine + lamivudine + nevirapine on CD4 counts 6months and 12 months after therapy. 3. To compare the efficacy of the above two mentioned regimens. Methods: In this retrospective study, data was collected from the antiretroviral therapy (ART) Centre where 46 subjects infected with HIV received stavudine + lamivudine + nevirapine and 54 subjects infected with HIV received zidovudine + lamivudine + nevirapine. Baseline CD4 counts were recorded and compared with CD4 counts after 6 months and 12 months after therapy in each regimen. Changes in CD4 counts in both the regimen were also compared. Statistical analysis was done using ANOVA followed by Tukey test for group wise comparison.  Results: Statistical analysis showed that there was no significant change in CD4 count after 6 months of treatment in stavudine group whereas there was significant increase in CD4 counts after 12 months after therapy with stavudine + lamivudine + nevirapine. But there was a significant increase in CD4 counts after both 6 months and 12 months of treatment with zidovudine + lamivudine + nevirapine. But when efficacy of both the regimen was compared with each other there was no significant change in the CD4 counts. Conclusion: This  nevirapine and zidovudine + lamivudine + nevirapine are equally efficacious but improvement of CD4 counts after initial 6 months of therapy is better with zidovudine + lamivudine + nevirapine treated group than compared with stavudine + lamivudine + nevirapine treated group. 


Keywords


HIV, Zidovudine, Stavudine, Lamivudine, nevirapine, CD4 Count.

Full Text:

PDF

References


UNAIDS/WHO AIDS Epidemic Update: December 2005. Available at:

http://www.unaids.org/epi/2005/doc/report.asp.

Anita R, AIDS in India: Incidence, Prevalence, and Prevention. AIDS Patient Care and STDs. May 2001, 15(5): 255-261.

Wei X, Ghosh SK, Taylor ME, Viral dynamics in HIV-1 infection. Nature. 1995; 373:117-122.

Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995; 373:123-126.

Saag MS, Holodniy M, Kuritzkes DR, HIV viral load markers in clinical practice. Nat Med. 1996; 2:625-629.

Hirsch MS, Conway B, D’Aquila RT, Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society—USA Panel. JAMA. 1998; 279: 1984-1991.

Yeni PG, Hammer SM, Hirsch MS, Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA. 2004; 292:251-265.

Egger M, May M, Chene G, Prognosis of HIV-1 infected drug naive patients starting potent antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360:119-129.

Lichtenstein K, Armon C, Buchacz K, Early, Uninterrupted ART is associated with improved outcomes and less toxicity in the HIV outpatient study (HOPS). In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 769.

World Health Organization.Progress on Global Access to HIV Antiretroviral Therapy. A Report on 3 by 5 and Beyond. March 2006. Available online at http://www.who.int/entity/hiv/progreport2006_en.pdf.

Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217–224.

British HIV Association. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). Available online at http://www.bhiva.org/guidelines/2005/HIV/guidelines2005.pdf.

Sharon S. Antiviral agents, In: Katzung BG editor. Basic and clinical pharmacology. 11th ed. Mc graw hill publications. New Delhi. 2009. P. 858-860.

Moore RD and Chaisson RE, Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999; 13:1933–1942.

Piantadosi S, Objectives and outcomes. In: Steven Piantadosi editor. Clinical Trials - A Methodologic Perspective. 2nd ed. John Wiley & Sons Publication. USA. 2005. p.200.

Flexner C, antiretroviral agents and treatment of HIV infection. In: Laurence LB editor. Goodmann and Gillmann’s The Pharmacological basis of therapeutics. 12th ed. Mc graw hill publications. New York. 2011. P. 1632-1634.

Christophe P, Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease AIDS. 1998; 12:745–750.


Refbacks

  • There are currently no refbacks.


 

Int.J.Bioassays is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

Creative Commons License